Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Immune Characteristics Associated with Lymphomatoid Granulomatosis and Outcome Following Treatment with Interferon-Alpha

Kieron Dunleavy, MD, Pratip Chattopadhyay, PhD, Junichi Kawada, Sara Calattini, Emma Gostick, PhD, David Price, MD, PhD, Mario Roderer, PhD, Jeffrey Cohen, MD, Nicole Grant, MPH, Stefania Pittaluga, MD, John E Janik, MD, Elaine S Jaffe, MD, Wyndham H. Wilson, MD, PhD

Blood (2010) 116 (21): 963.

https://doi.org/10.1182/blood.V116.21.963.963

Published: 2010

Journal Articles

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

Chunlin Chen, MD, PhD, John E Janik, MD, Karen Kaucic, MD, Lorin Roskos, PhD, Bahija Jallal, PhD, Gabriel J. Robbie, PhD

Blood (2009) 114 (22): 2670.

https://doi.org/10.1182/blood.V114.22.2670.2670

Published: 2009

Journal Articles

Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).

Kieron Dunleavy, MD, Stefania Pittaluga, MD, Kevin Tay, MD, Nicole Grant, MPH, Clara C Chen, MD, Margaret Shovlin, RN, Seth Steinberg, PhD, Louis M Staudt, MD, PhD, Elaine S Jaffe, MD, John E Janik, MD, Wyndham H Wilson, MD, PhD

Blood (2009) 114 (22): 106.

https://doi.org/10.1182/blood.V114.22.106.106

Published: 2009

Journal Articles

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Kamal Sharma, DO, John E. Janik, MD, Deirdre O’Mahony, MD, Donn Stewart, MD, Stefania Pittaluga, MD, Maryalice Stetler-Stevenson, MD, PhD, Elaine S. Jaffe, MD, Mark Raffeld, MD, Thomas A. Fleisher, MD, Cathryn C. Lee, NP, Nicole Urquhart, MD, Seth Steinberg, PhD, Thomas A. Waldmann, MD, John C. Morris, MD

Blood (2008) 112 (11): 2010.

https://doi.org/10.1182/blood.V112.11.2010.2010

Published: 2008

Journal Articles

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Deirdre O’Mahony, MD, John E Janik, MD, Jorge A. Carrasquillo, MD, Pamela Seam, MD, Joseph A Fiorillo, MD, Donn Stewart, MD, Chang H Paik, PhD, Suzanne Fioravanti, RN, Millie Whatley, RNMT, Stefania Pittaluga, MD, PhD, Martin W Brechbiel, PhD, John C Morris, MD, Thomas A Waldmann, MD

Blood (2008) 112 (11): 231.

https://doi.org/10.1182/blood.V112.11.231.231

Published: 2008

Journal Articles

Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R

Kieron Dunleavy, MD, Stefania Pittaluga, MD, PhD, Nicole Grant, MPH, Seth Steinberg, PhD, Margaret Shovlin, RN, Kevin Tay, MD, John E. Janik, MD, Elaine S. Jaffe, M.D., Wyndham H. Wilson, MD, PhD

Blood (2008) 112 (11): 3590.

https://doi.org/10.1182/blood.V112.11.3590.3590

Published: 2008

Journal Articles

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

Kieron Dunleavy, MD, Richard Little, MD, Alan S. Wayne, MD, Nicole Grant, MPH, Stefania Pittaluga, MD, PhD, Elaine S. Jaffe, MD, Seth Steinberg, PhD, Robert Yarchoan, MD, PhD, Jorge A. Carrasquillo, MD, John E. Janik, MD, Wyndham H. Wilson, MD, PhD

Blood (2008) 112 (11): 3606.

https://doi.org/10.1182/blood.V112.11.3606.3606

Published: 2008

Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Deirdre O’Mahony, MD, John C. Morris, MD, Maryalice Stetler-Stevenson, MD, Helen Matthews, RN, Stefania Pittaluga, MD, Paul Albert, PhD, Karen Kaucic, MD, Luz Hammershaimb, MD, Thomas A. Waldmann, MD, John E. Janik, MD

Blood (2007) 110 (11): 3565.

https://doi.org/10.1182/blood.V110.11.3565.3565

Published: 2007

Journal Articles

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Deirdre O’Mahony, MD, John C. Morris, MD, Leslie Moses, Diana O’Hagan, Wendy Gao, Maryalice Stetler-Stevenson, MD, Margaret Taylor, Luz Hammershaimb, MD, Thomas A. Waldmann, John E. Janik, MD

Blood (2005) 106 (11): 3353.

https://doi.org/10.1182/blood.V106.11.3353.3353

Published: 2005

Journal Articles

A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies.

John E. Janik, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD, Elaine S. Jaffe, MD, Nicole Grant, MPH, Margaret Shovlin, Maryalice Stetler-Stevenson, MD, Wyndham H. Wilson, MD

Blood (2005) 106 (11): 3348.

https://doi.org/10.1182/blood.V106.11.3348.3348

Published: 2005

NARROW

Immune Characteristics Associated with Lymphomatoid Granulomatosis and Outcome Following Treatment with Interferon-Alpha

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL).

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R

Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only